Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes (Lead-Ph)

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: liraglutide

Study type: Observational

Funder types: Industry

Identifiers

NCT01345734

NN2211-3932

U1111-1119-8803 (Other Identifier)

Details and patient eligibility

About

This trial is conducted in Asia. The aim of this trial is to investigate the safety profile of liraglutide under normal conditions of use.

Enrollment: 1,056 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects with type 2 diabetes mellitus, including newly-diagnosed subjects or those already receiving other anti-diabetic medications including GLP-1 analogues other than Liraglutide, who require treatment with liraglutide according to the clinical judgment of their treating physician
• Subjects who are capable of giving study-specific signed informed consent before any collection of information

Exclusion criteria

• Subjects with type 1 diabetes
• Subjects who are or have previously been on liraglutide
• Subjects who are participating in another clinical trial
• Subjects with a hypersensitivity to liraglutide or to any of the excipients (Disodium phosphate dihydrate, propylene glycol, phenol, water for injections)
• Subjects who are pregnant, breast feeding or have the intention of becoming pregnant within the following 6 months

Trial design

1,056 participants in 1 patient group

Liraglutide

Treatment:

Drug: liraglutide